The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation

Vascular Health and Risk Management

Volumn 3, Issue 5, 2007, Pages 567-577

  Gelosa, Paolo ^a   Cimino, Mauro ^b   Pignieri, Alice ^a   Tremoli, Elena ^a,c   Guerrini, Uliano ^a   Sironi, Luigi ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF URBINO   (Italy)

^c CENTRO CARDIOLOGICO MONZINO   (Italy)

Author keywords

Endothelial dysfunction; HMG CoA reductase; Inflammation; Nitric oxide; Statins

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ANGIOTENSIN 1 RECEPTOR; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EZETIMIBE; FARNESYL DIPHOSPHATE; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYFASUDIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; MEVALONIC ACID; MEVINOLIN; N(G) NITROARGININE METHYL ESTER; NITROPRUSSIDE SODIUM; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; REACTIVE OXYGEN METABOLITE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAVEOLA; CELL FUNCTION; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CORRELATION FUNCTION; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; HEART MUSCLE PERFUSION; HUMAN; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; ISOPRENYLATION; MOLECULAR MECHANICS; MONOTHERAPY; NONHUMAN; PLEIOTROPY; PROTEIN PROCESSING; PROTEIN SYNTHESIS INHIBITION; REVIEW;

ANIMALS; CAVEOLAE; DISEASE; ENDOTHELIAL CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; NITRIC OXIDE;

EID: 36148950538     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Ackermann A, Fernandez-Alfonso MS, Sanchez dR, et al. 1998. Modulation of angiotensin-converting enzyme by nitric oxide. Br J Pharmacol, 124:291-8.
2. Aikawa M, Rabkin E, Sugiyama S, et al. 2001. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation, 103:276-83.
3. Anderson TJ, Meredith IT, Yeung AC, et al. 1995. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med, 332:488-93.
4. Baldassarre D, Mores N, Colli S, et al. 1997. Platelet alpha 2-adrenergic receptors in hypercholesterolemia: relationship between binding studies and epinephrine-induced platelet aggregation. Clin Pharmacol Ther, 61:684-91.
5. Bassell G, Singer RH. 1997. mRNA and cytoskeletal filaments. Curr Opin Cell Biol, 9:109-15.
6. Behrendt D, Ganz P. 2002. Endothelial function. From vascular biology to clinical applications. Am J Cardiol, 90:40L-48L.
7. Bellosta S, Via D, Canavesi M, et al. 1998. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol, 18:1671-8.
8. Bernot D, Benoliel AM, Peiretti F, et al. 2003. Effect of atorvastatin on adhesive phenotype of human endothelial cells activated by tumor necrosis factor alpha. J Cardiovasc Pharmacol, 41:316-24.
9. Brown DA, London E. 2000. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem, 275:17221-4.
10. Buchwald H, Campos CT, Boen JR, et al. 1995. Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH). J Am Coll Cardiol, 26:351-7.
11. Campbell DJ, Habener JF. 1986. Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. J Clin Invest, 78:31-9.
12. Carneado I, Alvarez dS, Perez-Guerrero C, et al. 2002. Simvastatin improves endothelial function in spontaneously hypertensive rats through a superoxide dismutase mediated antioxidant effect. J Hypertens, 20:429-37.
13. Celermajer DS, Sorensen KE, Gooch VM, et al. 1992. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet, 340:1111-15.
14. Colli S, Eligini S, Lalli M, et al. 1997. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol, 17:265-72.
15. Colli S, Werba JP, Tremoli E. 2004. Statins in atherothrombosis. Semin Vasc Med, 4:407-15.
16. Corsini A, Bellosta S, Baetta R, et al. 1999. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther, 84:413-28.
17. Cortellaro M, Cofrancesco E, Arbusti E, et al. 2002. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost, 88:41-7.
18. Creager MA, Cooke JP, Mendelsohn ME, et al. 1990. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest, 86:228-34.
19. Davignon J. 2004. Beneficial cardiovascular pleiotropic effects of statins. Circulation, 109:III39-43.
20. de Sotomayor MA, Perez-Guerrero C, Herrera MD, et al. 1999. Effects of chronic treatment with simvastatin on endothelial dysfunction in spontaneously hypertensive rats. J Hypertens, 17:769-76.
21. de Sotomayor MA, Perez-Guerrero C, Herrrera MD, et al. 2005. Improvement of age-related endothelial dysfunction by simvastatin: effect on NO and COX pathways. Br J Pharmacol, 146:1130-38.
22. Dimmeler S, Fleming I, Fisslthaler B, et al. 1999. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature, 399:601-5.
23. Drexler H, Hayoz D, Munzel T, et al. 1992. Endothelial function in chronic congestive heart failure. Am J Cardiol, 69:1596-601.
24. Dzau VJ. 2001. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension, 37:1047-52.
25. Egashira K, Inou T, Hirooka Y, et al. 1993. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest, 91:29-37.
26. Eto M, Kozai T, Casentino F, et al. 2002. Statin prevents tissue factor expression inhuman endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation, 105:1756-9.
27. Fegan PG, Shore AC, Mawson D, et al. 2005. Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy. Diabetes Care, 22:1670-6.
28. Feron O, Dessy C, Desager JP, et al. 2001. Hydroxy-methylglutarylcoenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation, 103:113-18.
29. Feron O, Saldana F, Michel JB, et al. 1998. The endothelial nitric-oxide synthase-caveolin regulatory cycle. J Biol Chem, 273:3125-8.
30. Fichtlscherer S, Rosenberger G, Walter DH, et al. 2000. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation, 102:1000-6.
31. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, et al. 2006. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J, 27:1182-90.
32. Fulton D, Gratton JP, McCabe TJ, et al. 1999. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature, 399:597-601.
33. Ganz P, Vita JA. 2003. Testing endothelial vasomotor function: nitric oxide, a multipotent molecule. Circulation, 108:2049-53.
34. Gargalovic P, Dory L. 2003. Caveolins and macrophage lipid metabolism. J Lipid Res, 44:11-21.
35. Gauthier TW, Scalia R, Murohara T, et al. 1995. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol, 15:1652-9.
36. Gertz K, Laufs U, Lindauer U, et al. 2003. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke, 34:551-7.
37. Halcox JP, Deanfield JE. 2004. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation, 109:II42-8.
38. Harrison DG. 1997. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest, 100:2153-7.
39. Heeschen C, Hamm CW, Laufs U, et al. 2002. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation, 105:1446-52.
40. Hirata Y. 1996. Endothelin peptides. Curr Opin Nephrol Hypertens, 5:12-5.
41. Ichiki T, Takeda K, Tokunou T, et al. 2001. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 21:1896-901.
42. Ju H, Zou R, Venema VJ, et al. 1997. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J Biol Chem, 272:18522-5.
43. Kansui Y, Fujii K, Goto K, et al. 2004. Effects of fluvastatin on endothelium-derived hyperpolarizing factor- and nitric oxide- mediated relaxations in arteries of hypertensive rats. Clin Exp Pharmacol Physiol, 31:354-9.
44. Koh KK. 2000. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res, 47:648-57.
45. Koh KK, Ahn JY, Choi YM, et al. 2003. Vascular effects of step I diet in hypercholesterolemic patients with coronary artery disease. Am J Cardiol, 92:708-10.
46. Kumar KV, Das UN. 1997. Effect of cis-unsaturated fatty acids, prostaglandins, and free radicals on angiotensin-converting enzyme activity in vitro. Proc Soc Exp Biol Med, 214:374-9.
47. Landsberger M, Wolff B, Jantzen F, et al. 2007. Cerivastatin reduces cytokine-induced surface expression of ICAM-1 via increased shedding in human endothelial cells. Atherosclerosis, 190:43-52.
48. Laufs U, Endres M, Custodis F, et al. 2000. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation, 102:3104-10.
49. Laufs U, La Fata V, Plutzky J, et al. 1998. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 97:1129-35.
50. Laufs U, Liao JK. 1998. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem, 273:24266-71.
51. Laufs U, Liao JK. 2000. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med, 10:143-8.
52. Laufs U, Wassmann S, Hilgers S, et al. 2001. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol, 88: 1306-7.
53. Liao JK. 2002. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol, 86:5-18.
54. Li JJ, Li YS, Chen J, et al. 2006. Rebound phenomenon of inflammatory response may be a major mechanism responsible for increased cardiovascular events after abrupt cessation of statin therapy. Med Hypotheses, 66:1199-204.
55. Libby P, Ridker PM, Maseri A. 2002. Inflammation and atherosclerosis. Circulation, 105:1135-43.
56. Loch D, Levick S, Hoey A, et al. 2006. Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol, 47:396-404.
57. Mansourati J, Newman LG, Roman SH, et al. 2001. Lipid lowering does not improve endothelial function in subjects with poorly controlled diabetes. Diabetes Care, 24:2152-3.
58. Marui N, Offermann MK, Swerlick R, et al. 1993. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest, 92:1866-74.
59. Matsuo T, Iwade K, Hirata N, et al. 2005. Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia. Heart Vessels, 20:8-12.
60. Mollnau H, Wendt M, Szocs K, et al. 2002. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res, 90:E58-65.
61. Nakamura T, Saito Y, Ohyama Y, et al. 2004. Effect of cerivastatin on endothelial dysfunction and aortic CD36 expression in diabetic hyperlipidemic rats. Hypertens Res, 27:589-98.
62. Nasmyth K, Jansen RP. 1997. The cytoskeleton in mRNA localization and cell differentiation. Curr Opin Cell Biol, 9:396-400.
63. Nawawi H, Osman NS, Yusoff K, et al. 2003. Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia. Horm Metab Res, 35:479-85.
64. Ni W, Egashira K, Kataoka C, et al. 2001. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res, 89:415-21.
65. Nickenig G, Baumer AT, Temur Y, et al. 1999. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation, 100:2131-4.
66. Nickenig G, Sachinidis A, Michaelsen F, et al. 1997. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation, 95:473-8.
67. Nishimatsu H, Suzuki E, Satonaka H, et al. 2005. Endothelial dysfunction and hypercontractility of vascular myocytes are ameliorated by fluvastatin in obese Zucker rats. Am J Physiol Renal Physiol, 288: H1770-6.
68. Nobes CD, Hall A. 1999. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol, 144:1235-44.
69. Notarbartolo A, Davi G, Avema M, et al. 1995. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol, 15:247-51.
70. O'Driscoll G, Green D, Taylor RR. 1997. Simvastatin, an HMG-Coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation, 95:1126-31.
71. Opper C, Clement C, Schwarz H, et al. 1995. Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol. Atherosclerosis, 113:211-17.
72. Osamah H, Mira R, Sorina S, et al. 1997. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol, 44:77-83.
73. Palmer RM, Ferrige AG, Moncada S. 1987. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature, 327:524-6.
74. Park JK, Muller DN, Mervaala EM, et al. 2000. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int, 58:1420-30.
75. Pasceri V, Willerson JT, Yeh ET. 2000. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation, 102:2165-8.
76. Perez-Guerrero C, Alvarez dS, Jimenez L, et al. 2003. Effects of simvastatin on endothelial function after chronic inhibition of nitric oxide synthase by L-NAME. J Cardiovasc Pharmacol, 42:204-10.
77. Radomski MW, Rees DD, Dutra A, et al. 1992. S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol, 107:745-9.
78. Ridker PM. 2003. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol, 92:17K-22K.
79. Ridley AJ. 1995. Rho-related proteins: actin cytoskeleton and cell cycle. Curr Opin Genet Dev, 5:24-30.
80. Rikitake Y, Kim HH, Huang Z, et al. 2005. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke, 36:2251-7.
81. Robbie LA, Booth NA, Brown AJ, et al. 1996. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol, 16:539-45.
82. Romano M, Diomede L, Sironi M, et al. 2000. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest, 80:1095-1100.
83. Romano M, Mezzetti A, Marulli C, et al. 2000. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Investig Med, 48:183-9.
84. Salerno JC, Harris DE, Irizarry K, et al. 1997. An autoinhibitory control element defines calcium-regulated isofomas of nitric oxide synthase. J Biol Chem, 272:29769-77.
85. Scalia R, Gooszen ME, Jones SP, et al. 2001. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation, 103:2598-603.
86. Searles CD, Ide L, Davis ME, et al. 2004. Actin cytoskeleton organization and posttranscriptional regulation of endothelial nitric oxide synthase during cell growth. Circ Res, 95:488-95.
87. Simons K, Ehehalt R. 2002. Cholesterol, lipid rafts, and disease. J Clin Invest, 110:507-603.
88. Skaletz-Rorowski A, Lutchman M, Kureishi Y, et al. 2003. HMG-CoA reductase inhibitors promote cholesterol-dependent Akt/PKB translocation to membrane domains in endothelial cells. Cardiovasc Res, 57:253-64.
89. Smart EJ, Graf GA, McNiven MA, et al. 1999. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol, 19:7289-304.
90. 2+ sensitization. Circ Res, 91:83-4.
91. Sowers JR. 2002. Endothelial vasodilation effects of statins in type 2 diabetic patients: response to van Venrooij et al. Diabetes Care, 25:1242-3.
92. Stalker TJ, Lefer AM, Scalia R. 2001. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol, 133:406-12.
93. Sugiyama M, Ohashi M, Takase H, et al. 2005. Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels, 20:133-6.
94. Takemoto M, Egashira K, Usui M, et al. 1997. Important Tole of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest, 99:278-87.
95. Takemoto M, Liao JK. 2001. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol, 21:1712-19.
96. Tamai O, Matsuoka H, Itabe H, et al. 1997. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation, 95:76-82.
97. Tan KC, Chow WS, Tam SC, et al. 2002. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab, 87:563-8.
98. Taneva E, Borucki K, Wiens L, et al. 2006. Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. Am J Cardiol, 97:1002-6.
99. Thomas M, Mann J. 1998. Increased thrombotic vascular events after change of statin. Lancet, 352:1830-1.
100. Tomita H, Egashira K, Kubo-Inoue M, et al. 1998. Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arterioscler Thromb Vasc Biol, 18:1456-64.
101. Tousoulis D, Antoniades C, Bosinakou E, et al. 2005. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis, 178:359-63.
102. Treasure CB, Klein JL, Weintraub WS, et al. 1995. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med, 332:481-7.
103. Tsunekawa T, Hayashi T, Kano H, et al. 2001. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation, 104:376-9.
104. van der Harst P, Wagenaar LJ, Buikema H, et al. 2005. Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease. Am J Cardiol, 96:1361-4.
105. van Etten RW, de Koning EJ, Honing ML, et al. 2002. Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol, 22:799-804.
106. van Venrooij FV, van de Ree MA, Bots ML, et al. 2002. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care, 25:1211-16.
107. Vergnani L, Hatrik S, Ricci F, et al. 2000. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: key role of L-arginine availability. Circulation, 101:1261-6.
108. Wang HR, Li JJ, Huang CX, et al. 2005. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta, 353:53-60.
109. Wassmann S, Laufs U, Baumer AT, et al. 2001. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol, 59:646-54.
110. Weber C, Erl W, Weber KS, et al. 1997. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol, 30:1212-17.
111. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. 2001. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med, 7:687-92.
112. Widlansky ME, Gokce N, Keaney JF Jr. et al. 2003. The clinical implications of endothelial dysfunction. J Am Coll Cardiol, 42:1149-60.
113. Wolfrum S, Jensen KS, Liao JK. 2003. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol, 23:729-36.
114. WOSCOPS Study Group. 1998. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation, 97:1440-5.
115. Wu L, Girouard H, de Champlain J. 2000. Involvement of the cyclic GMP pathway in the superoxide-induced IP3 formation in vascular smooth muscle cells. J Hypertens, 18:1057-64.
116. Xing Y, Chen H, Hu DY. 2005. (Effects of withdrawal of statins on nitric oxide production in vascular endothelial cells]. Zhonghua Nei Ke.Za Zhi, 44:22-4.
117. Yamakuchi M, Greer JJ, Cameron SJ, et al. 2005. HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res, 96:1185-92.
118. Zapolska-Downar D, Siennicka A, Kaczmarczyk M, et al. 2004. Simvastatin modulates TNFalpha-induced adhesion molecules expression in human endothelial cells. Life Sci, 75:1287-302.
119. Zeiher AM, Fisslthaler B, Schray-Utz B, et al. 1995. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res, 76:980-6.
120. Zundel W, Swiersz LM, Giaccia A. 2000. Caveolin 1-mediated regulation of receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity by ceramide. Mol Cell Biol, 20:1507-14.